Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of …
Read MoreFrom The Telegraph, By Julia Bradshaw If clinical trials are successful, the British-developed jab could be available to patients within four to five years The world is one step closer to a vaccine against peanut allergy after UK biotech Allergy Therapeutics announced plans to test its jab in human clinical trials. The company, which was …
Read MoreGroup to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …
Read More